Roth Report, page-40

When buying a private company, you can pay a lot in milestone payments (that is, pay only if the drug continues to be successful). It's much harder to do so with a publicly listed company... As generally you'll need to pay all the amount upfront...Which the bios prefer not to do. It's much easier to commit 550 odd million of a billion dollar payment AFTER the drug is proven commercial.

Even so, if we just got the cash upfront payment of Biovex (420 odd US million) we're laughing...

So hopefully we'll see some movement at the station soon.